XORTX Therapeutics Inc. (XRTX)

2,5900 -0,3900 (-13,09%) Börsenschluss: 04:00PM EDT

XORTX Therapeutics Inc.

3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1
Canada
403 455 7727
https://www.xortx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 2

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Allen Warren Davidoff Ph.D.	Founder, CEO, President & Director	357,67k	N/A	1960
Mr. James Neville Fairbairn C.A., C.P.A., ICD.D	Interim Chief Financial Officer	42,67k	N/A	1963
Dr. Stephen Haworth M.D., MRCP	Chief Medical Officer	227,87k	N/A	1950
Dr. Stacy Evans M.B.A., M.D.	Chief Business Officer	84,35k	N/A	1974
Nick Rigopoulos	Director of Communications	N/A	N/A	N/A
Dr. David Sans M.B.A., Ph.D.	Director of Corporate Development	N/A	N/A	1970
Dr. David MacDonald Ph.D.	Consultant of Clinical Operations	N/A	N/A	1964
Ms. Charlotte May	Corporate Secretary	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and acute kidney injury (AKI) associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. The company has a collaboration and license agreements with the Icahn School of Medicine to study the incidence of AKI and hyperuricemia in patients hospitalized with COVID-19; and with the University of Florida Research Foundation, Inc. XORTX Therapeutics Inc. is based in Alberta Beach, Canada.

Corporate Governance

XORTX Therapeutics Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.